Cadila Healthcare is currently trading at Rs. 660.00, up by 14.05 points or 2.18% from its previous closing of Rs. 645.95 on the BSE.
The scrip opened at Rs. 655.85 and has touched a high and low of Rs. 665.00 and Rs. 650.00 respectively. So far 2039 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 964.00 on 12-Sep-2012 and a 52 week low of Rs. 631.00 on 20-Aug-2013.
Last one week high and low of the scrip stood at Rs. 690.00 and Rs. 631.00 respectively. The current market cap of the company is Rs. 13513.40 crore.
The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 15.34% and 9.87% respectively.
Zydus Cadila has received the final approval from the USFDA to market Lansoprazole DR Capsules in different strengths of 15mg and 30mg. The drug falls in the anti-ulcerant segment. The estimated sales in 2012 as per IMS for Lansoprazole DR Capsules were $501 million.
The group has now 81 approvals and has so far filed 186 ANDAs since the commencement of filing process in FY2003-04.
Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: